The extracellular signal-regulated kinases 1 and 2 (ERK1/2), also known as MAPK3 and MAPK1 respectively, represent the terminal effectors of the canonical RAS-RAF-MEK-ERK mitogen-activated protein kinase (MAPK) signaling cascade. This pathway fundamentally governs cellular processes including proliferation, differentiation, survival, and migration, with its dysregulation being a hallmark of numerous malignancies. Consequently, pharmacological intervention targeting ERK1/2 phosphorylation has emerged as a critical strategy in both experimental oncology and clinical therapeutics. Inhibitors of ERK1/2 phosphorylation can be broadly categorized into two mechanistic classes: indirect inhibitors that target upstream kinases—primarily MEK1/2—and direct inhibitors that bind ERK1/2 itself, each offering distinct advantages and limitations in research and clinical applications.

Indirect ERK1/2 phosphorylation inhibitors, predominantly MEK1/2 inhibitors, constitute the most extensively characterized and clinically validated approach to blocking ERK activation. Since MEK1 and MEK2 are the sole known dual-specificity kinases capable of phosphorylating and activating ERK1/2 on threonine and tyrosine residues within the TEY activation motif, pharmacological MEK inhibition effectively prevents ERK phosphorylation entirely. In laboratory research, compounds such as U0126, PD98059 (CAS No.167869-21-8), and PD0325901 serve as standard tools for investigating MAPK pathway function, with U0126 being particularly ubiquitous in cell culture experiments for demonstrating pathway-specific effects through Western blot analysis of phospho-ERK levels. The clinical translation of MEK inhibition has yielded several FDA-approved agents including trametinib (Mekinist), cobimetinib (Cotellic), binimetinib (Mektovi), and selumetinib (Koselugo), which have demonstrated significant efficacy in BRAF-mutant melanoma and other malignancies. However, a critical limitation of MEK inhibitors is their propensity to induce feedback reactivation of the pathway; by relieving negative feedback inhibition at the level of RAF, MEK blockade can paradoxically increase upstream signaling, potentially limiting therapeutic durability and necessitating combination strategies.

Direct ERK1/2 inhibitors represent a more recent pharmacological innovation designed to overcome the limitations of upstream targeting. These compounds bind directly to ERK1/2 and block kinase activity through multiple mechanisms. ATP-competitive inhibitors such as ulixertinib (BVD-523), the most clinically advanced direct ERK inhibitor, ravoxertinib (GDC-0994), and LY3214996 occupy the ATP-binding pocket, preventing phosphate transfer to downstream substrates. Notably, some direct inhibitors including SCH772984 exhibit dual mechanisms, simultaneously blocking ERK catalytic activity and interfering with MEK-mediated phosphorylation. A crucial mechanistic distinction exists between these approaches: while MEK inhibitors abolish detectable phospho-ERK signal, direct ERK inhibitors may permit or even enhance ERK phosphorylation due to loss of negative feedback regulation, despite the kinase remaining catalytically inactive. Therefore, assessment of direct ERK inhibitor efficacy requires monitoring downstream substrate phosphorylation (e.g., p-RSK, p-ELK1) rather than phospho-ERK levels alone. This pharmacological property has significant implications for biomarker development and patient selection in clinical trials.

Recent advances in ERK1/2 inhibitor development have revealed important insights regarding compensatory signaling mechanisms and resistance. Research has demonstrated that selective ERK1/2 inhibition can induce compensatory activation of ERK5 (MAPK7), a related MAPK family member that promotes cancer cell survival and limits therapeutic efficacy, particularly in triple-negative breast cancer. This observation has catalyzed the development of dual-targeting strategies, exemplified by SKLB-D18, a first-in-class single-molecule inhibitor that simultaneously targets ERK1/2 and ERK5 by occupying their ATP-binding sites concurrently. Preclinical studies demonstrate that such dual inhibition achieves synergistic antiproliferative effects with combination index values below 0.2, substantially outperforming selective ERK1/2 inhibitors in overcoming drug resistance. These findings highlight the ERK1/2-ERK5 axis as an emerging therapeutic target and underscore the importance of considering pathway redundancy in inhibitor design.

The therapeutic application of ERK1/2 phosphorylation inhibitors extends beyond oncology into inflammatory and neurodegenerative diseases, though cancer remains the primary indication. In colorectal carcinoma models, COX-2 inhibitors such as the novel vicinal diaryl-substituted heterocycle VA1213 have demonstrated significant antitumor activity through suppression of ERK1/2 and AKT phosphorylation, inducing G0/G1 cell cycle arrest and caspase-3-dependent apoptosis. This example illustrates how targeting upstream signaling nodes can effectively modulate ERK activity in specific pathological contexts. For clinical practitioners and researchers, the selection between direct and indirect ERK inhibition strategies requires careful consideration of the biological context, resistance mechanisms, and appropriate biomarkers for monitoring therapeutic response.